Finally, neratinib as monotherapy as well as in combination with temsirolimus or trastuzumab in NSCLC patients with HER2 alteration produced inferior ORR (0%–14%) and DCR (28%–49%) compared with poziotinib, pyrotinib, trastuzumab emtansine and trastuzumab deruxtecan. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.